Pall ForteBio Introduces Off-the-Shelf Dip and Read Anti-CHO HCP Detection Kit to Accelerate Drug Development
Pall ForteBio, a division of Pall Corp. has announced commercial availability of a new Dip and Read Anti-CHO (Chinese hamster ovary) Host Cell Protein (HCP) Detection Kit for quantitation of residual HCPs. Kit users benefit from faster time to results, enhanced range of detection and better assay precision, all of which accelerate the drug development timeline while improving safety and efficacy. The kit can also be applied in production phases to confirm reduction or removal of HCP, increasing efficiency and speed of production.
The kit combines the Pall ForteBio Octet platform for rapid high-throughput protein analysis with the broad HCP recognition and sensitivity of the industry-standard Cygnus 3G anti-CHO HCP antibody. The high-precision assays have 5–10% CVs, and the design allows the analysis to be done, without supervision, in 65–90 minutes.
“The commonly used ELISA HCP analytical method can require up to overnight analysis and must be monitored. Our new Dip and Read high-precision assay kit, in combination with the Octet HTX system, is hands-free, and only takes around an hour to analyse 96 samples with detection sensitivity as low as 0.5 ng/mL,” said Yves Baratelli, President of Pall Life Sciences. “This translates into a dramatic advance in the user’s process, and a drastic reduction in their time and capital investment from development through to production.”
As the most commonly used mammalian hosts for industrial production of recombinant protein therapeutics, CHO cells often leave behind contaminating HCPs. The residuals can substantially decrease the efficacy of a drug product, or even cause immunogenic reactions in patients. Therefore, detection and reduction of residual HCP contaminants is critical for drug safety and qualification.
“The HCP detection kit complements the use of Octet systems for protein titer measurement and residual protein A contaminant detection in bioprocessing. So far the feedback from customers has been exceptional. More than six key customers from large biopharmaceutical companies have completed beta testing with the product,” Robert Wicke, Sr. VP for Instrumentation R&D at Pall ForteBio, said. “It is a great complement to our full detection line, all supported by Octet instruments.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance